The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer

By Xin-wei Qiao, Jian Jiang, Xin Pang, Mei-chang Huang, Ya-Jie Tang, Xin-hua Liang, Ya-ling Tang. 2020

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Heterogeneity of PD-L1 Expression Between the Primary Tumor and Matched Lymph Node Metastases in Head and Neck Squamous Cell Carcinomas (2026, unknown): “Head and neck cancer is one of the most immune-inflamed human tumors, but response rates to PD-1 checkpoint inhibition, which represents the first-line treatment in recurrent and metastatic cases, are modest [21].”
Prognostic impact of intra- and peritumoral immune cell subpopulations in head and neck squamous cell carcinomas – comprehensive analysis of the TCGA-HNSC cohort and immunohistochemical validation on 101 patients (2023, background): “Head and neck cancer is one of the most immune-inflamed human tumors, but response rates to PD-1 checkpoint inhibition are modest (27) resulting in a persistently poor prognosis with fiveyear survival rates of 50-60% (8).”
Unraveling the Role of Tumor-Infiltrating Immune Cells in Head and Neck Squamous Cell Carcinoma: Implications for Antitumor Immune Responses and Immunotherapy (2025, unknown): “The widely described PD-1/PD-L1 axis participates in modulating immune cells and other stromal cells and has been proposed as an additional potential mechanism for immunosuppression, facilitating immune evasion and resistance [74].”